Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant Medications Altering Gastric pH and Gastric Motility in Healthy Subjects
Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of conc...
Saved in:
| Published in | Antimicrobial agents and chemotherapy Vol. 58; no. 7; pp. 4020 - 4025 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.07.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0066-4804 1098-6596 1098-6596 |
| DOI | 10.1128/AAC.02448-13 |
Cover
Loading…
| Abstract | Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a ≥10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum (
T
max
), and apparent terminal half-life (
t
1/2
) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC
0–inf
) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88–1.20) with antacid, 0.97 (0.84–1.12) with ranitidine, 1.01 (0.87–1.17) with esomeprazole, and 0.93 (0.79–1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum (
C
max
) were 1.06 (0.90–1.26) with antacid, 1.04 (0.88–1.23) with ranitidine, 1.05 (0.89–1.24) with esomeprazole, and 0.86 (0.73–1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility. |
|---|---|
| AbstractList | Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a ≥ 10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum (Tmax), and apparent terminal half-life (t1/2) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC0-inf) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88-1.20) with antacid, 0.97 (0.84-1.12) with ranitidine, 1.01 (0.87-1.17) with esomeprazole, and 0.93 (0.79-1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum (Cmax) were 1.06 (0.90-1.26) with antacid, 1.04 (0.88-1.23) with ranitidine, 1.05 (0.89-1.24) with esomeprazole, and 0.86 (0.73-1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility.Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a ≥ 10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum (Tmax), and apparent terminal half-life (t1/2) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC0-inf) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88-1.20) with antacid, 0.97 (0.84-1.12) with ranitidine, 1.01 (0.87-1.17) with esomeprazole, and 0.93 (0.79-1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum (Cmax) were 1.06 (0.90-1.26) with antacid, 1.04 (0.88-1.23) with ranitidine, 1.05 (0.89-1.24) with esomeprazole, and 0.86 (0.73-1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility. Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a ≥10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum ( T max ), and apparent terminal half-life ( t 1/2 ) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC 0–inf ) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88–1.20) with antacid, 0.97 (0.84–1.12) with ranitidine, 1.01 (0.87–1.17) with esomeprazole, and 0.93 (0.79–1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum ( C max ) were 1.06 (0.90–1.26) with antacid, 1.04 (0.88–1.23) with ranitidine, 1.05 (0.89–1.24) with esomeprazole, and 0.86 (0.73–1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility. Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a ≥ 10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum (Tmax), and apparent terminal half-life (t1/2) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC0-inf) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88-1.20) with antacid, 0.97 (0.84-1.12) with ranitidine, 1.01 (0.87-1.17) with esomeprazole, and 0.93 (0.79-1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum (Cmax) were 1.06 (0.90-1.26) with antacid, 1.04 (0.88-1.23) with ranitidine, 1.05 (0.89-1.24) with esomeprazole, and 0.86 (0.73-1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility. Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a greater than or equal to 10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum (Tmax), and apparent terminal half-life (t1/2) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC0-inf) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88-1.20) with antacid, 0.97 (0.84-1.12) with ranitidine, 1.01 (0.87-1.17) with esomeprazole, and 0.93 (0.79-1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum (Cmax) were 1.06 (0.90-1.26) with antacid, 1.04 (0.88-1.23) with ranitidine, 1.05 (0.89-1.24) with esomeprazole, and 0.86 (0.73-1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility. Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fasting state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). There was a ≥10-day washout between treatment periods. Posaconazole exposure, time to maximum concentration of drug in serum (Tmax), and apparent terminal half-life (t1/2) were similar when posaconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90% confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC0–inf) (posaconazole with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88–1.20) with antacid, 0.97 (0.84–1.12) with ranitidine, 1.01 (0.87–1.17) with esomeprazole, and 0.93 (0.79–1.09) with metoclopramide. Geometric mean ratios (90% CIs) of the maximum concentration of drug in serum (Cmax) were 1.06 (0.90–1.26) with antacid, 1.04 (0.88–1.23) with ranitidine, 1.05 (0.89–1.24) with esomeprazole, and 0.86 (0.73–1.02) with metoclopramide. In summary, in healthy volunteers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent when posaconazole was administered alone or with medications affecting gastric pH or gastric motility. |
| Author | Krishna, Gopal Waskin, Hetty Chang, Peter S. van Iersel, Marlou L. P. S. Kraft, Walter K. Kersemaekers, Wendy M. |
| Author_xml | – sequence: 1 givenname: Walter K. surname: Kraft fullname: Kraft, Walter K. organization: Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA – sequence: 2 givenname: Peter S. surname: Chang fullname: Chang, Peter S. organization: Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA – sequence: 3 givenname: Marlou L. P. S. surname: van Iersel fullname: van Iersel, Marlou L. P. S. organization: MSD, Oss, Netherlands – sequence: 4 givenname: Hetty surname: Waskin fullname: Waskin, Hetty organization: Merck & Co., Inc., Whitehouse Station, New Jersey, USA – sequence: 5 givenname: Gopal surname: Krishna fullname: Krishna, Gopal organization: Merck & Co., Inc., Whitehouse Station, New Jersey, USA – sequence: 6 givenname: Wendy M. surname: Kersemaekers fullname: Kersemaekers, Wendy M. organization: MSD, Oss, Netherlands |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28577263$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24798274$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1vEzEQhi1URNPCjTPyBYlKbPF3HA5IUVQapFRUopytWcfbON2107WDlP4GfjQOCeFDIHGyx_PM6_G8PkFHIQaH0HNKzill-s14PDknTAhdUf4IDSgZ6UrJkTpCA0KUqoQm4hidpLQkJZYj8gQdMzEcaTYUA_T1OiawMcBDbB2-gbp1GV8voO_K6Z0PLnub3uIZ2DscG3zRNM7m7W4Sg42dzxAyvnJzbyH7GBIet9n1PtziS0i59xavphjC_BBexexbnzfYBzx10ObFBn9a18sim56ixw20yT3br6fo8_uLm8m0mn28_DAZzyoQmuaKMauF4yBACbCMNY1owGlwklLLa12XJJlbyalyvExGaVVbCpJaIWmp4Kfo3U53ta47N7cu5B5as-p9B_3GRPDm90zwC3MbvxhBlJacFYFXe4E-3q9dyqbzybq2heDiOhkqxUhxTpj6H3SolZScFPRsh0LqmFnGdR_KFAwlZmu0KUab70Ybygv74tcnHHr_4WwBXu4BSBbapodgffrJaTkclvYK93rH2T6m1LvmgPzjXvYHbssf2FpfBuXbvxd9A7Tb0mo |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1177_1078155216673228 crossref_primary_10_1007_s12325_020_01341_x crossref_primary_10_1007_s13318_018_0513_7 crossref_primary_10_1016_j_ijpharm_2017_10_051 crossref_primary_10_1097_FTD_0000000000000235 crossref_primary_10_3390_jof6040281 crossref_primary_10_3389_fphar_2020_575463 crossref_primary_10_1002_phar_1533 crossref_primary_10_1016_j_ijantimicag_2019_01_006 crossref_primary_10_1016_j_ijantimicag_2023_106995 crossref_primary_10_1007_s15010_017_1042_z crossref_primary_10_1007_s40265_022_01819_8 crossref_primary_10_1111_myc_13031 crossref_primary_10_3390_jof9020144 crossref_primary_10_1093_cid_ciw360 crossref_primary_10_1016_j_ijantimicag_2016_04_013 crossref_primary_10_1097_QCO_0000000000000103 crossref_primary_10_1007_s40265_015_0348_3 crossref_primary_10_1093_jac_dkv380 crossref_primary_10_1128_AAC_02465_17 crossref_primary_10_1586_14787210_2015_1032939 crossref_primary_10_1093_jac_dkx228 crossref_primary_10_1007_s12281_015_0224_3 crossref_primary_10_1111_myc_12948 crossref_primary_10_1128_AAC_00484_19 crossref_primary_10_3390_pharmacy3040210 crossref_primary_10_1080_17425255_2020_1764939 crossref_primary_10_3390_separations4020016 crossref_primary_10_1007_s40265_020_01306_y crossref_primary_10_1080_10428194_2022_2126282 crossref_primary_10_1128_AAC_00188_17 crossref_primary_10_1002_jps_24690 crossref_primary_10_1155_2017_3460892 crossref_primary_10_1080_14656566_2021_1996562 crossref_primary_10_1093_mmy_myw001 crossref_primary_10_1080_17425255_2019_1671971 crossref_primary_10_1038_s41598_018_20136_3 crossref_primary_10_1177_1078155217722405 crossref_primary_10_1007_s12281_017_0287_4 crossref_primary_10_1128_AAC_00101_17 crossref_primary_10_1093_jat_bkv030 crossref_primary_10_1007_s40588_015_0019_x crossref_primary_10_1128_AAC_04035_14 crossref_primary_10_1016_j_xphs_2016_03_027 crossref_primary_10_1111_myc_12911 crossref_primary_10_1007_s12281_016_0255_4 crossref_primary_10_3390_antibiotics10111330 crossref_primary_10_1002_cpt_1529 crossref_primary_10_1097_FTD_0000000000000371 crossref_primary_10_1016_j_cca_2015_08_023 crossref_primary_10_1111_bcp_13707 crossref_primary_10_1002_pbc_30782 crossref_primary_10_1111_cts_12658 crossref_primary_10_3390_biomedicines5040066 crossref_primary_10_1016_j_rmr_2016_08_008 crossref_primary_10_1007_s12281_022_00430_4 crossref_primary_10_1007_s15015_018_3890_5 crossref_primary_10_1093_jac_dkab312 crossref_primary_10_1128_AAC_01166_17 crossref_primary_10_1080_17425255_2016_1181752 crossref_primary_10_1016_j_cmi_2024_07_019 crossref_primary_10_1111_myc_12724 crossref_primary_10_1097_QCO_0000000000000277 crossref_primary_10_1111_myc_12326 crossref_primary_10_1111_myc_12524 crossref_primary_10_1128_CMR_00032_16 crossref_primary_10_1093_jac_dkx440 crossref_primary_10_1128_AAC_02061_17 crossref_primary_10_1016_j_rmed_2021_106492 crossref_primary_10_1093_jac_dkx122 crossref_primary_10_5863_1551_6776_26_7_753 crossref_primary_10_1016_j_antinf_2016_01_002 crossref_primary_10_1093_mmy_myz015 crossref_primary_10_1007_s11910_018_0824_8 crossref_primary_10_1007_s40262_018_0658_1 crossref_primary_10_1586_17512433_2015_1034689 crossref_primary_10_1128_aac_01085_22 crossref_primary_10_1128_AAC_00581_15 crossref_primary_10_3390_ma16206616 crossref_primary_10_3390_jof1030345 crossref_primary_10_1128_aac_00077_23 |
| Cites_doi | 10.1046/j.1365-2125.2003.01977.x 10.1056/NEJMoa061094 10.2165/00003495-200565110-00007 10.1128/AAC.50.5.1881-1883.2006 10.1592/phco.27.12.1627 10.1016/j.jpba.2006.06.011 10.1128/AAC.47.9.2788-2795.2003 10.1128/AAC.50.2.658-666.2006 10.1128/AAC.00889-09 10.1086/503425 10.1086/508774 10.1056/NEJMoa061098 10.3324/haematol.2011.049627 10.1185/03007990903485056 10.1592/phco.28.10.1223 10.1128/AAC.00222-12 10.1128/AAC.01034-08 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS Copyright © 2014, American Society for Microbiology. All Rights Reserved. Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T7 8FD C1K FR3 P64 7X8 5PM |
| DOI | 10.1128/AAC.02448-13 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE Engineering Research Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1098-6596 |
| EndPage | 4025 |
| ExternalDocumentID | PMC4068532 02448-13 24798274 28577263 10_1128_AAC_02448_13 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM - 0R 55 AAPBV ABFLS ADACO BXI HZ RHF ZA5 7T7 8FD C1K FR3 P64 7X8 5PM |
| ID | FETCH-LOGICAL-a481t-22c84e3a4a64ac22ff4fae8ae511c3b8b4e30dc5316e3244686bc1a51c4514ac3 |
| ISSN | 0066-4804 1098-6596 |
| IngestDate | Thu Aug 21 13:55:13 EDT 2025 Fri Jul 11 09:12:35 EDT 2025 Fri Jul 11 06:27:36 EDT 2025 Tue Dec 28 13:58:56 EST 2021 Thu Apr 03 07:04:24 EDT 2025 Wed Apr 02 07:28:57 EDT 2025 Tue Jul 01 04:32:23 EDT 2025 Thu Apr 24 23:09:13 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Human Drug Stomach Motility Healthy subject Digestive system Azole derivatives Antifungal agent Triazole derivatives Dosage form pH Tablet Pharmacokinetics Posaconazole |
| Language | English |
| License | CC BY 4.0 Copyright © 2014, American Society for Microbiology. All Rights Reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a481t-22c84e3a4a64ac22ff4fae8ae511c3b8b4e30dc5316e3244686bc1a51c4514ac3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Present address: Gopal Krishna, Cubist Pharmaceuticals, Lexington, Massachusetts, USA. |
| OpenAccessLink | https://aac.asm.org/content/aac/58/7/4020.full.pdf |
| PMID | 24798274 |
| PQID | 1547865530 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4068532 proquest_miscellaneous_1549633026 proquest_miscellaneous_1547865530 asm2_journals_10_1128_AAC_02448_13 pubmed_primary_24798274 pascalfrancis_primary_28577263 crossref_primary_10_1128_AAC_02448_13 crossref_citationtrail_10_1128_AAC_02448_13 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-07-01 |
| PublicationDateYYYYMMDD | 2014-07-01 |
| PublicationDate_xml | – month: 07 year: 2014 text: 2014-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2014 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_16_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_20_2 e_1_3_2_10_2 e_1_3_2_21_2 e_1_3_2_5_2 Merck & Co. (e_1_3_2_7_2) 2012 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 Pille S (e_1_3_2_18_2) 1998; 174 Merck Sharp & Dohme Limited (e_1_3_2_8_2) 2012 16641468 - Antimicrob Agents Chemother. 2006 May;50(5):1881-3 17251530 - N Engl J Med. 2007 Jan 25;356(4):335-47 18823218 - Pharmacotherapy. 2008 Oct;28(10):1223-32 20001450 - Curr Med Res Opin. 2010 Feb;26(2):397-405 19075045 - Antimicrob Agents Chemother. 2009 Mar;53(3):958-66 19738015 - Antimicrob Agents Chemother. 2009 Nov;53(11):4749-52 16033292 - Drugs. 2005;65(11):1553-67; discussion 1568-9 14748822 - Br J Clin Pharmacol. 2004 Feb;57(2):218-22 12936975 - Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95 16619151 - Clin Infect Dis. 2006 May 15;42(10):1398-403 17143808 - Clin Infect Dis. 2007 Jan 1;44(1):2-12 18041883 - Pharmacotherapy. 2007 Dec;27(12):1627-36 22615291 - Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201 16859858 - J Pharm Biomed Anal. 2007 Jan 4;43(1):228-36 16436724 - Antimicrob Agents Chemother. 2006 Feb;50(2):658-66 21859736 - Haematologica. 2011 Dec;96(12):1855-60 9830458 - Strahlenther Onkol. 1998 Nov;174 Suppl 3:52-5 17251531 - N Engl J Med. 2007 Jan 25;356(4):348-59 AbuTarif, MA, Krishna, G, Statkevich, P (B8) 2010; 26 Krishna, G, Moton, A, Ma, L, Medlock, MM, McLeod, J (B12) 2009; 53 Krishna, G, Tarif, MA, Xuan, F, Martinho, M, Angulo, D, Cornely, OA (B13) 2008; 28 Raad, II, Hachem, RY, Herbrecht, R, Graybill, JR, Hare, R, Corcoran, G, Kontoyiannis, DP (B3) 2006; 42 Walsh, TJ, Raad, I, Patterson, TF, Chandrasekar, P, Donowitz, GR, Graybill, R, Greene, RE, Hachem, R, Hadley, S, Herbrecht, R, Langston, A, Louie, A, Ribaud, P, Segal, BH, Stevens, DA, van Burik, JAH, White, CS, Corcoran, G, Gogate, J, Krishna, G, Pedicone, L, Hardalo, C, Perfect, JR (B5) 2007; 44 Krishna, G, Ma, L, Vickery, D, Yu, X, Wu, I, Power, E, Beresford, E, Komjathy, S (B10) 2009; 53 Ullmann, AJ, Cornely, OA, Burchardt, A, Hachem, R, Kontoyiannis, DP, Topelt, K, Courtney, R, Wexler, D, Krishna, G, Martinho, M, Corcoran, G, Raad, I (B15) 2006; 50 Keating, GM (B2) 2005; 65 Krishna, G, Ma, L, Martinho, M, O'Mara, E (B19) 2012; 56 Ullmann, AJ, Lipton, JH, Vesole, DH, Chandrasekar, P, Langston, A, Tarantolo, SR, Greinix, H, Morais de Azevedo, W, Reddy, V, Boparai, N, Pedicone, L, Patino, H, Durrant, S (B4) 2007; 356 Krishna, G, Martinho, M, Chandrasekar, P, Ullmann, AJ, Patino, H (B11) 2007; 27 Sansone-Parsons, A, Krishna, G, Calzetta, A, Wexler, D, Kantesaria, B, Rosenberg, MA, Saltzman, MA (B14) 2006; 50 Pille, S, Bohmer, D (B17) 1998; 174 (B6) 2012 Courtney, R, Pai, S, Laughlin, M, Lim, J, Batra, V (B9) 2003; 47 Cornely, OA, Maertens, J, Winston, DJ, Perfect, J, Ullmann, AJ, Walsh, TJ, Helfgott, D, Holowiecki, J, Stockelberg, D, Goh, Y-T, Petrini, M, Hardalo, C, Suresh, R, Angulo-Gonzalez, D (B1) 2007; 356 (B7) 2012 Courtney, R, Wexler, D, Radwanski, E, Lim, J, Laughlin, M (B16) 2004; 57 Shen, JX, Krishna, G, Hayes, RN (B20) 2007; 43 Vehreschild, MJ, Meissner, AM, Cornely, OA, Maschmeyer, G, Neumann, S, Von Lilienfeld-Toal, M, Karthaus, M, Wattad, M, Staib, P, Hellmich, M, Christ, H, Vehreschild, JJ (B18) 2011; 96 |
| References_xml | – ident: e_1_3_2_17_2 doi: 10.1046/j.1365-2125.2003.01977.x – ident: e_1_3_2_2_2 doi: 10.1056/NEJMoa061094 – volume-title: Noxafil (posaconazole) oral suspension, summary of product characteristics year: 2012 ident: e_1_3_2_8_2 – ident: e_1_3_2_3_2 doi: 10.2165/00003495-200565110-00007 – ident: e_1_3_2_15_2 doi: 10.1128/AAC.50.5.1881-1883.2006 – ident: e_1_3_2_12_2 doi: 10.1592/phco.27.12.1627 – ident: e_1_3_2_21_2 doi: 10.1016/j.jpba.2006.06.011 – ident: e_1_3_2_10_2 doi: 10.1128/AAC.47.9.2788-2795.2003 – ident: e_1_3_2_16_2 doi: 10.1128/AAC.50.2.658-666.2006 – ident: e_1_3_2_11_2 doi: 10.1128/AAC.00889-09 – ident: e_1_3_2_4_2 doi: 10.1086/503425 – ident: e_1_3_2_6_2 doi: 10.1086/508774 – ident: e_1_3_2_5_2 doi: 10.1056/NEJMoa061098 – volume: 174 start-page: 52 year: 1998 ident: e_1_3_2_18_2 article-title: Options for artificial nutrition of cancer patients publication-title: Strahlenther. Onkol. – ident: e_1_3_2_19_2 doi: 10.3324/haematol.2011.049627 – ident: e_1_3_2_9_2 doi: 10.1185/03007990903485056 – ident: e_1_3_2_14_2 doi: 10.1592/phco.28.10.1223 – ident: e_1_3_2_20_2 doi: 10.1128/AAC.00222-12 – volume-title: Noxafil (posaconazole) oral suspension prescribing information year: 2012 ident: e_1_3_2_7_2 – ident: e_1_3_2_13_2 doi: 10.1128/AAC.01034-08 – reference: 19738015 - Antimicrob Agents Chemother. 2009 Nov;53(11):4749-52 – reference: 20001450 - Curr Med Res Opin. 2010 Feb;26(2):397-405 – reference: 21859736 - Haematologica. 2011 Dec;96(12):1855-60 – reference: 16641468 - Antimicrob Agents Chemother. 2006 May;50(5):1881-3 – reference: 16436724 - Antimicrob Agents Chemother. 2006 Feb;50(2):658-66 – reference: 12936975 - Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95 – reference: 17251531 - N Engl J Med. 2007 Jan 25;356(4):348-59 – reference: 18041883 - Pharmacotherapy. 2007 Dec;27(12):1627-36 – reference: 9830458 - Strahlenther Onkol. 1998 Nov;174 Suppl 3:52-5 – reference: 16619151 - Clin Infect Dis. 2006 May 15;42(10):1398-403 – reference: 22615291 - Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201 – reference: 19075045 - Antimicrob Agents Chemother. 2009 Mar;53(3):958-66 – reference: 17251530 - N Engl J Med. 2007 Jan 25;356(4):335-47 – reference: 16033292 - Drugs. 2005;65(11):1553-67; discussion 1568-9 – reference: 17143808 - Clin Infect Dis. 2007 Jan 1;44(1):2-12 – reference: 16859858 - J Pharm Biomed Anal. 2007 Jan 4;43(1):228-36 – reference: 14748822 - Br J Clin Pharmacol. 2004 Feb;57(2):218-22 – reference: 18823218 - Pharmacotherapy. 2008 Oct;28(10):1223-32 – volume: 44 start-page: 2 year: 2007 end-page: 12 ident: B5 article-title: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial publication-title: Clin. Infect. Dis. doi: 10.1086/508774 – volume: 96 start-page: 1855 year: 2011 end-page: 1860 ident: B18 article-title: Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients publication-title: Haematologica doi: 10.3324/haematol.2011.049627 – volume: 42 start-page: 1398 year: 2006 end-page: 1403 ident: B3 article-title: Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions publication-title: Clin. Infect. Dis. doi: 10.1086/503425 – year: 2012 ident: B6 publication-title: Noxafil (posaconazole) oral suspension prescribing information ;Merck & Co. ;Whitehouse Station, NJ – volume: 50 start-page: 658 year: 2006 end-page: 666 ident: B15 article-title: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.50.2.658-666.2006 – volume: 56 start-page: 4196 year: 2012 end-page: 4201 ident: B19 article-title: A single dose phase I study to evaluate the pharmacokinetics of posaconazole new tablet and capsule formulations relative to oral suspension publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00222-12 – volume: 28 start-page: 1223 year: 2008 end-page: 1232 ident: B13 article-title: Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome publication-title: Pharmacotherapy doi: 10.1592/phco.28.10.1223 – volume: 47 start-page: 2788 year: 2003 end-page: 2795 ident: B9 article-title: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.47.9.2788-2795.2003 – volume: 57 start-page: 218 year: 2004 end-page: 222 ident: B16 article-title: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults publication-title: Br. J. Clin. Pharmacol. doi: 10.1046/j.1365-2125.2003.01977.x – volume: 53 start-page: 958 year: 2009 end-page: 966 ident: B12 article-title: The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01034-08 – year: 2012 ident: B7 publication-title: Noxafil (posaconazole) oral suspension, summary of product characteristics ;Merck Sharp & Dohme Limited ;Hertfordshire, United Kingdom – volume: 65 start-page: 1553 year: 2005 end-page: 1567 ident: B2 article-title: Posaconazole publication-title: Drugs doi: 10.2165/00003495-200565110-00007 – volume: 43 start-page: 228 year: 2007 end-page: 236 ident: B20 article-title: A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2006.06.011 – volume: 27 start-page: 1627 year: 2007 end-page: 1636 ident: B11 article-title: Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease publication-title: Pharmacotherapy doi: 10.1592/phco.27.12.1627 – volume: 50 start-page: 1881 year: 2006 end-page: 1883 ident: B14 article-title: Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.50.5.1881-1883.2006 – volume: 26 start-page: 397 year: 2010 end-page: 405 ident: B8 article-title: Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome publication-title: Curr. Med. Res. Opin. doi: 10.1185/03007990903485056 – volume: 356 start-page: 335 year: 2007 end-page: 347 ident: B4 article-title: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa061098 – volume: 53 start-page: 4749 year: 2009 end-page: 4752 ident: B10 article-title: Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00889-09 – volume: 356 start-page: 348 year: 2007 end-page: 359 ident: B1 article-title: Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa061094 – volume: 174 start-page: 52 year: 1998 end-page: 55 ident: B17 article-title: Options for artificial nutrition of cancer patients publication-title: Strahlenther. Onkol. |
| SSID | ssj0006590 |
| Score | 2.4517093 |
| Snippet | Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new posaconazole tablet formulation has... |
| SourceID | pubmedcentral proquest asm2 pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 4020 |
| SubjectTerms | Adult Antacids - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal Agents Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Antifungal Agents - pharmacokinetics Area Under Curve Biological and medical sciences Clinical Therapeutics Drug Interactions Female Gastric Acid Gastric Acid - physiology Gastrointestinal Motility Gastrointestinal Motility - physiology Healthy Volunteers Histamine H1 Antagonists - pharmacology Humans Hydrogen-Ion Concentration Male Medical sciences Middle Aged Pharmacology. Drug treatments Proton Pump Inhibitors - pharmacology Tablets Triazoles Triazoles - administration & dosage Triazoles - adverse effects Triazoles - pharmacokinetics Young Adult |
| Title | Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant Medications Altering Gastric pH and Gastric Motility in Healthy Subjects |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24798274 https://journals.asm.org/doi/10.1128/AAC.02448-13 https://www.proquest.com/docview/1547865530 https://www.proquest.com/docview/1549633026 https://pubmed.ncbi.nlm.nih.gov/PMC4068532 |
| Volume | 58 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqIRASQjBu5TIZBHvJUlrHuZS3agIVtqIiOm1vkeM6rGJLqiV92H4Df4__wzm2k6ZVhwYvUS4niaPz5VzscyHkbRBMhZqqnutP-4HLo6l0hQpTFxguuwmoeM4xUXj0NRge8S8n_kmr9bsRtbQok4682phX8j9chXPAV8yS_QfO1g-FE7AP_IUtcBi2N-LxOC9AoGXiCkMEJ5gEVTpjW4v6J5iPWIIZXf5DIXX8uC1VjBEYeQYDmmELYbtWYyLiBrh4ruekBDb0kM58qJcXqsNRXs604a5LZGHomJY9OJlTNO3cQVbOzme6yBMWI_ih8-h0Ct2pOrdJX_Vk_sGFMLrgWK_dOwedRtCBkUU6jNj5Xl_ArKvPYLmaGIORuDjLF85hxxl3GkTHorDNxoaqNOVOqgmOHq-DYWuhHSCKTJfijjJyGsugBr5phlsJcj9qADZsSGX0kRsaHg79zdqDYUbEYLDfAcuFg3ftLbVkFRmwpjzrkEbtTLEohrtjfXeMvZRvMfBeUF8cfFsWsYdxm8wo-11VPgaL3jffDUaCKM7ZisF0by4K-HdT03Rlk1e0HtzbsJYmD8h96-bQgcHsQ9JS2Ta5bRqfXm6TOyMb0rFNdi1gL_foZJkLWOzRXTpellW_fER-NdFODdrpOto_UMQ6zVNqsI57DazTBtZphXVqwU3nQwoQrQ8rrNNZRi3WaYX1x-To08fJ_tC1vURcwaNe6TImI648wUXAhWQsTXkqVCQUOBzSS6IELnanEjRSoMDH4EEUJLIn_J7kIK-E9J6QrSzP1DNC0xBuBa8_kSE8zlNJmvb7kRcxGXoeZ2GbvEG-xVZQFPEmaLSJU3E1lrYaPzaFObuG-l1NPTdVaK6h21kBSE3MIh-AGADB6woxMegRXBwUmcoXMEgs7BdgE7G_0oC-9rosaJOnBmXLN_CwH7GQt0m4gr-aAOvYr17JZqe6nj34FOA0sOc3_MgX5O5STLwkW-XFQr0Cz6BMdvR_9gdIaA9m |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Posaconazole+Tablet+Pharmacokinetics%3A+Lack+of+Effect+of+Concomitant+Medications+Altering+Gastric+pH+and+Gastric+Motility+in+Healthy+Subjects&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Kraft%2C+Walter+K.&rft.au=Chang%2C+Peter+S.&rft.au=van+Iersel%2C+Marlou+L.+P.+S.&rft.au=Waskin%2C+Hetty&rft.date=2014-07-01&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=58&rft.issue=7&rft.spage=4020&rft.epage=4025&rft_id=info:doi/10.1128%2FAAC.02448-13&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_AAC_02448_13 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |